Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC

Wu Y.-L.John T.Grohe C.Majem M.Goldman J.W.Kim S.-W.Kato T.Laktionov K.Vu H.V.Wang Z.Lu S.Lee K.Y.Akewanlop C.CHONG-JEN YUde Marinis F.Bonanno L.Domine M.Shepherd F.A.Zeng L.Atasoy A.Herbst R.S.Tsuboi M.2022-06-272022-06-2720221556-0864https://www.scopus.com/inward/record.uri?eid=2-s2.0-85114022603&doi=10.1016%2fj.jtho.2021.10.014&partnerID=40&md5=ea3b60859594f6a5c0cd40b7a2bddb02https://scholars.lib.ntu.edu.tw/handle/123456789/613973[SDGs]SDG3Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLCjournal article10.1016/j.jtho.2021.10.014347408612-s2.0-85114022603